Outcomes over the first two years of treatment with mepolizumab in severe asthma

Eur Respir J. 2021 Dec 23;58(6):2101313. doi: 10.1183/13993003.01313-2021. Print 2021 Dec.


This study found that 30% of patients stopped mepolizumab in the second year of treatment. Those with a sustained response had lower blood eosinophils and better asthma control questionnaire scores prior to starting mepolizumab. https://bit.ly/3ChWN63

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Asthmatic Agents* / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Asthma* / drug therapy
  • Humans


  • Anti-Asthmatic Agents
  • Antibodies, Monoclonal, Humanized
  • mepolizumab